{"nctId":"NCT02631551","briefTitle":"Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)","startDateStruct":{"date":"2016-03"},"conditions":["Seasonal Allergic Rhinitis"],"count":1180,"armGroups":[{"label":"GSP 301 NS","type":"EXPERIMENTAL","interventionNames":["Drug: GSP 301 NS"]},{"label":"Olopatadine HCl NS","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olopatadine HCl NS"]},{"label":"Mometasone furoate NS","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mometasone furoate NS"]},{"label":"GSP 301 Placebo NS","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: GSP 301 Placebo NS"]}],"interventions":[{"name":"GSP 301 NS","otherNames":[]},{"name":"Olopatadine HCl NS","otherNames":[]},{"name":"Mometasone furoate NS","otherNames":[]},{"name":"GSP 301 Placebo NS","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged 12 years and older inclusive of either sex.\n2. Documented clinical history of SAR (for at least 2 years preceding the Screening Visit \\[Visit 1\\]) with exacerbations (clinical evidence of active symptoms) during the spring allergy season (tree/grass pollen)\n3. A 12-hour reflective TNSS ≥ 8 out of a possible 12 and a congestion score of ≥ 2 for the AM assessment at the Screening Visit (Visit 1).\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Plans to travel outside the known pollen area for the investigative site for \\> 24 hours during the last 7 days of run in period.\n3. History of anaphylaxis and/or other severe local reaction(s) to skin testing.\n4. History of positive test for HIV, Hepatitis B or Hepatitis C infection.\n5. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.\n6. Subjects with an active pulmonary disorder or infection.\n7. Subjects with posterior subcapsular cataracts or glaucoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptoms Score (rTNSS) From Baseline to End of Treatment.","description":"Reflective Total Nasal Symptom Score (rTNSS) was calculated as the sum of 12-hour reflective scoring of the severity of four nasal symptoms (nasal congestion, rhinorrhea, nasal itching, sneezing). Subjects responded on a 4-point severity scale with scores ranging from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate). The rTNSS was calculated as the sum of the subject-reported severity scores for nasal symptoms, and value ranged from 0 (no signs/symptoms evident) to 12 (severe signs/symptoms that is hard to tolerate).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"1.2"},{"groupId":"OG001","value":"10.3","spread":"1.3"},{"groupId":"OG002","value":"10.2","spread":"1.2"},{"groupId":"OG003","value":"10.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"3.2"},{"groupId":"OG001","value":"-3.2","spread":"3.1"},{"groupId":"OG002","value":"-3.5","spread":"3.3"},{"groupId":"OG003","value":"-2.8","spread":"3.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":302},"commonTop":[]}}}